Background: In the various cancer, mast cells (MCs) infiltration is correlated with a worse prognosis. There is an increasing evidence that MCs and their mediators are participated in remodeling of the tumor microenvironment and facilitate tumor growth, epithelial-to-mesenchymal transition (EMT) and metastasis. Methods: The transwell was conducted to evaluate the correlations between MCs and non-small cell lung cancer (NSCLC) cells in vitro. The RNA interference of β-catenin was performed to further explore the signaling pathway. Lung adenocarcinoma cell line A549 and human MC (HMC-1) were subcutaneously injected into BALB/c nude mice. The conventional experiment methods (such as quantitative RT-PCR Western Blot, Immunofluorescence, and ELISA) were used in the present study. Results: We found that high density of MCs in NSCLC correlates with worse prognosis. The NSCLC cells could release CCL5 and recruit MCs to the tumor microenvironment. Then, we explored that HMC-1 transplantation accelerated the growth of A549 cell in nude mice. Moreover, the MCs-derived factors were responsible for tumor growth. When NSCLC cells were activated, MCs produced various factors that induced EMT and migration. We also identified that CXCL8/interleukin (IL)-8 served as the major modulator containing in the activated MC conditioned medium. Furthermore, MCs and exogenous IL-8 promoted β-catenin phosphorylation in NSCLC cells. Inhibiting the Wnt/β-catenin pathway by RNA interference could revert EMT and migration of NSCLC. Conclusions: Our study suggests that MCs are recruited into NSCLC microenvironment and improve the EMT and migration of cancer cells, thereby accelerating the growth of NSCLC.
Introduction
Lung cancer is the most common malignant disease of solid tumors in human. In recent decades, the incidence rate of lung cancer has been steadily increasing by 13% each year. Among these,
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International Publisher approximate 85% are non-small cell lung cancer (NSCLC) and about 33% of diagnosed patients with NSCLC have already reached the metastatic phase because of epithelial-to-mesenchymal transition (EMT) and migration [1] [2] .
Immune cells, which are an important component of tumor stroma, mediate cancer progress by either inhibiting or facilitating tumor EMT and metastasis [3] . NSCLC micro-environment is affluent in a variety of immune cells, including lymphocytes, macrophages, and mast cells (MCs) [4] . It is well known that MCs play a key role in the tumor EMT and migration [5] . MCs are existed in bone marrow, heterogeneous immune cells that are involved in innate and adaptive immune by releasing preformed or newly synthesized soluble modulators [6] . However, the role of MCs in cancer is still unclear, only few data indicate that MCs own the function in tumor improvement [7] . It is reported that MC density correlates with poor prognosis in many types of cancers result from inducing EMT and invasiveness by MCs [8] . It is interesting to us that MCs can be benefit of suppressing immune response to resist tumors [9] . Some studies have proved that human NSCLC exhibits a MC infiltrate along with worse overall survival and disease-free survival [10] [11] . However, the underlying mechanism of MCs promote NSCLC migration and EMT is still unknown.
We previously have demonstrated that cancer cells recruit MCs in a tumor microenvironment by secreting many cytokines and chemoattractants such as IL-6, TNF-α, GM-CSF, CXCL8/IL-8, and CXCL1/IP10, which can exacerbate the malignant phenotype of cancer cells [12] . Here we assessed the cellular crosstalk between MCs regulator and NSCLC cells in the modulation of EMT and migration. We found that human NSCLC feature has a significant MCs infiltrate whose intensity is positive correlation with the worse prognosis. According to chemo-attraction assays, we demonstrated that NSCLC cells recruit MCs to the tumor micro-environment through releasing of C-C motif chemokine ligand 5(CCL5) which the receptor CCR3 exists on the MCs surface [13] . The human MCs (HMC-1) were recruited to NSCLC cells by the tail vein injection of nude mice in xenografts. Here we show that NSCLC cell conditioned medium (CM) could produce a variety of cytokines with high expressions in HMC-1. Administration of NSCLC cells with CM from tumor educated MC (MC CM) induced EMT and migration. We further showed that MC-derived IL-8 was the predominant modulator to induce EMT and migration through the Wnt/β-catenin pathway.
Materials and Methods

Tissue samples and cell lines
Tissue samples were obtained from 56 cases of histology-confirmed NSCLC at the department of Thoracic Medicine Department, Hunan Cancer Hospital (Changsha, China). These patients have not received any chemotherapy or radiation therapy before surgery and were pathologically diagnosed as NSCLC. The present study was approved by the Ethics Committee of Hunan Cancer Hospital and written informed consent was obtained from each patient before the participation.
Cell lines (HBE, A549, and SPC-α-1) were kindly obtained from the (Xiangya Hospital of Central South University) and they were cultured in Roswell Park Memorial Institute-1640 (RPMI-1640; Sigma, USA) medium supplemented with 10% fetal calf serum (FCS; Invitrogen, Carlsbad, CA, USA), 100 IU/ml penicillin and 100 IU/ml streptomycin at 37 C in a humid atmosphere with 5% CO2. The human MCs (HMC-1) were culture in Iscove's Modified Dulbecco's Medium (IMDM) medium containing 10% fetal bovine serum (FBS; Invitrogen) according to our previous description [14] . Human bronchial epithelial cells (HBECs) CM was used as a negative control.
Preparation of conditioned medium
For generating CM of NSCLC cells, NSCLC cells were cultured up in growth medium providing with 5% FBS. These supernatants were carefully collected, filtered and preserved as the cultured medium to stimulate MCs and NSCLC cells. NSCLC cells CM is termed as the control medium throughout the experiments. For producing CM of MCs, MCs were starved overnight and after that the medium was changed with the NSCLC cells CM and these cells were incubated overnight. Subsequently these supernatants were collected, filtered and preserved at -80°C. These MCs were termed as 'tumor educated' MCs and the collected medium was named MC CM.
Mast cell recruitment and NSCLC cells assay in vitro
A 24-well transwell chamber (Corning, NY, USA) was used to assess the ability of MC recruitment in vitro. Briefly, 2.5 × 10 4 NSCLC cells CM were seeded in the lower chamber, then 1 × 10 5 MCs were seeded into the upper compartment. The upper and lower compartments were divided by an 8 μm polycarbonate membrane coated with 10 μg/ml fibronectin (Santa Cruz, CA, USA). The chambers were placed at CO2 incubator with 37 °C for 4 h. Subsequently, the samples were filtered, scraped, and fixed in 4% paraformaldehyde for 20 min. After that, they were washed with PBS and stained with 0.1% crystal violet. Cell migration was assayed by calculating the number of cells. Each experiment was measured in triplicate in the present study.
To evaluate the migrating ability of NSCLC cells, NSCLC cells (1x10 4 ) were incubated in the top compartment with serum-free medium in each Transwell insert (Corning Costar, Corning). The MC CM was added to the bottom chambers and cells were incubated with 37 °C for 24 h. The antibodies of α-IL-6, α-IL-8 and α-TNFα were obtained from R&D Systems (Bio-Techne, USA). The next step was the same as MCs recruitment assay.
RNA extraction, cDNA synthesis, and quantitative RT-PCR
NSCLC cells which stimulated with MC CM for 48 h were homogenized in 1 mL of the TRIzol reagent (Invitrogen, USA) to isolate total RNA following the manufacturer's instructions. RNA was then reversely transcribed into cDNA using the All-in-OneTM First Strand cDNA Synthesis kit (AORT-0050; GeneCopoeia, Shanghai, China). Quantitative real-time PCR (qRT-PCR) was conducted on StepOnePlusTM Real-Time PCR Systems (Applied Biosystems, Foster City, CA, USA) using the PowerUp SYBR® Green Master Mix (Applied Biosystems). The target primers used for qRT-PCR were described in our previous work [14] . β-actin served as a normalization.
ELISA assay and histamine release
MCs were starved overnight and treated with NSCLC cells CM overnight. The cytokines and chemoattractants in the MC CM were measured by ELISA (R&D Systems) according to manufacturer's instructions. Histamine release was conducted using a histamine ELISA kit (IBL, Hamburg, Germany).
Western blot analysis
Protein extractions and immunoblotting analysis were exhibited as described in previous study [15] . In brief, NSCLC cells were performed by either MC CM or control medium with/without the stimulation of recombinant IL-8. After that, the protein lysates were gathered after 1 h, 12 h, and 24 h. The following antibodies were used: primary anitbody of vimentin (D21h3, 1:1,000; Cell Signaling Technology (CST), Danvers, USA), E-cadherin (ab76055, 1:1,000; Abcam, Cambridge, USA), GAPDH (14C10, 1:1,000; CST), β-catenin (D10A8, 1:1,000; CST), and secondary antibody of goat anti-rabbit (1:5,000) and goat anti-mouse (1:5,000) (Invitrogen). Protein bands were calculated and quantified with the Image J software. The β-actin was normalized as the control.
Immunohistochemical analysis
The NSCLC tissue test was constructed using 56 cases from the department of Thoracic Medicine Department, Hunan Cancer Hospital. Informed consent was received from all investigated patients in the present study. All diagnosis of tumors and controls was carefully assessed by an experienced pathologist. The information of the primary antibodies was as following: anti-human tryptase (clone AA1, 1:200; Abcam), vimentin (D21h3, 1:200; CST), and E-cadherin (ab76055, 1:200; Abcam). Specifically, each sample was scored according to our previous experiments [14] .
Immunofluorescence
The tumor tissue with protein-blocking serum free solution (Dako, Denmark) was collected and they were incubated with the primary antibodies overnight at 4°C. After the sections were washed with TBST (TBS with Tween 20) and incubated with fluorescent dye-conjugated secondary antibodies for 1 h at room temperature, nuclear staining was conducted with 6-diamidino-2-phenylindole, dihydrochloride (DAPI, Invitrogen). The following antibody was incubated with c-Kit (clone AK2, eBioscience). The specific protocol was according to our former study [15] .
In vivo mast cell recruitment assay
All mouse experiments were performed following the rules of the Animal Center of Hunan Cancer Hospital. 1 × 10 7 NSCLC cells were suspended in matrigel (1:8; BD Biosciences, San Jose, USA) and were subcutaneously injected into the right dorsal area of male BALB/c nude mice. When the volume of the xenografts attained about 40 mm 3 , the mice were intravenously injected with HMC-1 (approximately 1 × 10 6 with each mouse). Mice were then sacrificed at 1, 2, and 7 d after the injection. To further validate the role of role of CCL5 in the recruitment of MCs in NSCLC in vivo, the CCL5-siRNA were synthesized by Shanghai GenePhama Co., Ltd. (Shanghai, China) and transfected to A549 cell. The CCL5-siRNA sequence was S: 5'-GCCCACAUCAAGGAGUAUUTT-3', A:5'-AAUACUCCUUGAUGUGGGCTT-3'.
Experiments in mice
The 4 weeks' old male BALB/c nude mice were applied according to our previous research [14] . For animal experiments, we subcutaneously injected into the right dorsal portion of these nude mice with lung adenocarcinoma cell line A549 (1x10 7 per mouse), HMC-1 (1x10 6 per mouse) or mixed together (A549 and HMC-1). The length (termed as "a") and the width (termed as "b") of the xenografts of tumors were examined in mice. The xenograft volumes (termed as "V") were analyzed acccoding to the formula, V (mm 3 ) = a × b 2 /2. The mice were killed post 3 weeks' injection and tumor xenografts were collected, removed, weighed, and photographed. Then, the sections were further performed using hematoxylin and eosin (H&E) staining, western blot, immunohistochemistry, and qRT-PCR.
Statistical analysis
Statistical significance was assessed by Student's unpaired t-test in different experiment groups. Furthermore, for the comparison analysis over two groups, the ANOVA software was used. GraphPad Prism 6 software (San Diego, USA) was conducted and a "p" value < 0.05 was considered statistically significant.
Results
Mast cell increased in human NSCLC and correlated with worse prognosis
We analyzed MCs infiltrate in 56-paired primary NSCLC and distant normal tissues (at least 5 cm distal to the tumor lesion). Compared with normal samples, NSCLC samples expressed much more infiltration in MCs. A typical example of cell staining by tryptase antibody was presented in Figure 1A and 1B.
For exploring the correction between clinic-pathological features, prognosis and MCs infiltrate, NSCLC samples were divided into two groups: one with high expression of tryptase (+++, ++) which represented 68% (38 of 56) of collected patients; the other one with lower expression of tryptase (+, -), which represented 32% (18 of 56). The group of NSCLC samples with intense tryptase staining seemed to be the advance stage (P < 0.05). However, the tryptase staining is not correlated with age, gender and pathological pattern and lymph node metastasis (Table 1) . These results suggested that MCs infiltrate in NSCLC tissues were much higher compared with the normal lung tissues. MCs presence and more intensity positively correlated with worse prognosis ( Figure 1C , HR = 3.49, 95% CI was 1.44-8.45, P=0.005).
Recruitment of mast cells by NSCLC cells: a role for CCL5
To evaluate how did the MCs recruitment to the tumor micro-environment by NSCLC cells, we performed chemotaxis assays in vitro. We examined the capacity of CM from the NSCLC cell lines (1 × 10 5 A549 and 1 × 10 5 SPC-α-1) in the lower chambers. Then the 1 × 10 5 MCs were seeded in the upper chambers to induce the migration potency of MCs according to a fibronectin matrix. The data indicated that CM from each cell line (A549 and SPC-α-1) could induce the migration of HMC-1 (Figure 2A) . The results indicated that some cytokines secreted by NSCLC cells were responsible for the chemoattractant effect on HMC-1. Further analysis suggested that a candidate for the chemoattractant role is CCL5, and others have validated that NSCLC cells produce CCL5, and HMC-1 express CCL5 receptor CCR1 [16] [17] . As shown in Figure 2B , NSCLC cells produce high level of CCL5, but not HBECs. Once we neutralized the CCL5 in the A549 CM, the MCs chemotaxix effect was inhibited ( Figure 2C ). These data demonstrated that NSCLC cells secreted CCR5 to induce MCs recruitment. 
NSCLC cells induce mast cell activation
Once the MCs activation, it can release histamine, cytokines and chemokines. Figure 3A showed that both A549 and SPC-α-1 CM concentration stimulated histamine which is released from A549 and SPC-α-1CM, respectively. The MCs was treated with A549 and SPC-α-1 CM to validate whether NSCLC CM could enhance transcriptional levels. Figure 3B showed that the protein levels of IL-6, TNF-α, and CXCL8/IL-8 were significantly up-regulated in A549 and SPC-α-1 CM for 24 h.
MC CM induces EMT and invasion ability of NSCLC cells
We could obtain the HMC-1 CM which were activated by A549 CM or SPC-α-1 CM. Figure 4A showed that both MC CM and transforming growth factor beta (TGF-β) was a positive reference [18] , and they induced significantly different morphology in A549 and SPC-α-1 cell line, which is EMT. Furthermore, we examined the protein level of EMT transcription factors Zeb-1, epithelium marker E-cadherin, and interstitial marker Vimentin in NSCLC cells treated with MC CM, which were collected at different time points (3, 12 , and 24 h). These results showed that such treatment induced EMT in each analyzed NSCLC cell line ( Figure 4B ). The result showed that MC CM enhanced the A549 and SPC-α-1 migration ( Figure 4C ), which was a typical EMT. These characteristics indicated that MC CM might release some soluble factors to trigger EMT and migration. 
IL-8 is the main MC-derived soluble factor inducing EMT and migration in NSCLC cells
We showed increased protein level of IL-6, TNF-α, and IL-8 in tumor-educated MCs. In addition, we suggested that IL-6, IL-8, and TNF-α had the ability to induce EMT transcription factor ZEB1 as well as epithelium marker E-cadherin and interstitial marker Vimentin expression in A549 and SPC-α-1 cells ( Figure 5A ). Inhibiting IL-8, but no change of IL-6 or TNF-α from MC CM, significantly prevented cell migration of NSCLC, and the migration ability was recovered by IL-8 addition ( Figure 5B ). These data suggested that IL-8 was the key mediators for MC CM-mediated EMT in NSCLC. Accordingly, we found that NSCLC cell lines were significantly increased levels of IL-8 receptors, CXCR1 and CXCR2 (Data not shown). These data demonstrated that tumor-educated MCs released IL-8, subsequently induced CXCR1 and CXCR2 expression, eventually elevated tumor EMT and migration in NSCLC.
Molecular mechanisms involved in IL-8-induced EMT and invasion in NSCLC cells
Then we investigated which signaling pathway was involved in IL-8 and MC CM-induced EMT and migration. It is well known that overexpression of Wnt/β-catenin is correlated with worse NSCLC prognosis [19] . In our previous study, we have proved that miR-33b restrains the Wnt/β-catenin signaling activation in lung adenocarcinoma cells and then inhibits EMT, migration and growth of tumor cells. Knockdown of β-catenin in NSCLC cells inhibits the tumor and migration [14] . We found that IL-8 induced the activation of β-catenin in SPC-α-1 using the MC CM culture with A549 cell lines (Figure 6A-B) . Knockdown of β-catenin significantly inhibited IL-8-induced EMT by assessing ZEB1, E-cadherin, Vimentin mRNA expression ( Figure  6C ). Furthermore, the results showed that β-catenin-siRNA inhibit tumor migration (Figure 6 D) . The same data were validated in SPC-α-1 (Data not shown). Our results indicated that IL-8 activated EMT and migration through Wnt/β-catenin pathway in NSCLC cells.
Xenografts of human NSCLC cells can recruit circulating mast cells
To confirm whether HMC-1 could be recruited into tumor region in vivo, we injected A549 cell (1 × 10 7 ) subcutaneously nude mice. When the tumors was measured approximately 40 mm 3 , and 5 × 10 6 HMC-1 cells were intravenously injected into mice tail. To further validate the role of role of CCL5 in the recruitment of MCs in NSCLC in vivo, the CCL5-siRNA were synthesized by Shanghai GenePhama Co., Ltd. (Shanghai, China) and transfected to A549 cell. The results showed only injection of HMC-1 cells were recruitment to the tumor, but not in non-injected controls. However, the down-regulation of CCL5 in A549 cell, the role of HMC-1 cells recruitment to the tumor was inhibited ( Figure 7B ). Scarcely any MCs were existed at the 1 d after injection (only 5-7 in the whole lung tissue), but their number were significantly enhanced at 7d post injection ( Figure 7A ). 
Mast cells enhance the xenograft growth and EMT of human NSCLC cells in vivo
To further clarify the underlying mechanism, we injected 1 × 10 7 A549 cells, 1 × 10 6 HMC-1 cells or mixture of both cells (A549 and HMC-1) into the BALB/c nude mice. As shown in Figure 8A , when A549 cells were co-injected with HMC-1 cells, tumor volume was obviously higher than those of A549 cells injection alone (P < 0.001). Immunohistochemistry assay showed that the expressions of ZEB1, β-catenin and vimentin were increased, whereas E-cadherin levels were down-regulated after 21 d injection in cells mixture xenografts, which was consistent with the data in vitro ( Figure 8B ). The qRT-PCR data was uniform with western blot result ( Figure 8C and D) . Taken together the results showed that MC induced tumor growth by promoting EMT of NSCLC cells.
Discussion
MCs are infiltrated in a variety of tumors which they regulate antitumorigenic or protumorigenic role [8, [20] [21] . Chronic inflammatory reactions predispose to mediate cancer progress by either inhibiting or promoting tumor EMT and metastasis [3] . This response involves chemokines CCL5, and CCL5 is also identified in human NSCLC samples, which mediates TGF-β expression, where it correlates with lung adenocarcinoma invasion [22] . RUNX3 is the up-stream receptor of CCL5, and decreasing the RUNX3 expression can improve cancer-associated bone destruction in NSCLC [16] . Interestingly, CCL5 induces human MC migration by activating CCR1 and CCR4, which are the MC receptors located in the surface of human umbilical cord blood derived MC or human lung tissue derived MC [17, 22] . We discovered that the density of MC is much higher in human NSCLC tissue than in normal lung tissue. This phenomenon may be explained by the following reasons: once MC recruits to the tumor tissue can increase proliferation of resident mast cells and NSCLC can induce MC migration to the tumor micro-environment. According to chemoattraction assays, we show that NSCLC maybe play a potential role for MCs chemoattractant. This effect needs CCL5 which is derived from NSCLC cell, and it is restrained by the anti-CCL5 antibody. Interestingly, HMC-1 cells are recruited to NSCLC cell xenografts after injection into the tail vein of nude mice. When mixed NSCLC cells and HMC-1 cells were subcutaneously transplanted, and it can promote tumor growth. This result proves that NSCLC cells provide MCs with a suitable condition that eventually improves their survival and cell growth. We also show that NSCLC cells CM induces MC activation by secreting a variety of cytokines and chemoattractants such as IL-6, TNF-α, GM-CSF, CXCL8/IL-8, and CXCL1/IP10, which can aggravate the malignant phenotype of cancer cells [12] . In the present research, MC-derived soluble factors mediate NSCLC cell EMT and migration. Moreover, we stimulate MCs with NSCLC cell-derived CM and find some cytokines significantly upregulated compared with vehicle group including IL-6, IL-8, and TNF-α, which is consistent with the expression in NSCLC cells for inducing EMT and migration. Interestingly, we also discover that IL-8 is needed for modulating MC CM migration in A549 cells by immune depletion experiments. Consistently, CXCR1 and CXCR2 are expressed in NSCLC cells. There are many explanations, and we think different inflammatory factors or other stress-related cytokines result in IL-8 activation from MCs in a cancer microenvironment [19, 23] . In the present study, we suggest that IL-8 serves as the main MC-derived cytokine inducing EMT and migration in NSCLC cells.
Furthermore, we explore the underlying mechanism that IL-8 induces NSCLC migration and EMT. IL-8 not only involves in the innate and adaptive immunity in mammals, but also is associated with a variety of activation in many cancers. Specifically, IL-8 is involved in many kinds of tumor growth due to its ability to trigger cell invasion, migration and angiogenesis [24] [25] [26] . IL-8 also has been proved for involving in tumor EMT [27] . Here, we suggest that IL-8 is increased in plasma of NSCLC patients compared to the normal control especially with worse prognosis [28] [29] . IL-8, as the up-stream of Wnt/β-Catenin, can induce the activation of Wnt in tumor and reduce the phosphorylation of β-Catenin degradation to induce tumor EMT and migration [19] . It is reported that IL-32 secreted by gastric cancer cells can induce the downstream chemokines IL-8 expression to promote tumor metastasis by modulating the Wnt/β-Catenin signaling pathway [30] . IL-8 can also play the role of promoting tumor EMT and metastasis by targeting Wnt/β-Catenin pathway in ovarian cancer cells [31] . In our study, knockdown of β-Catenin impedes EMT transcription factors ZEB1 accumulation and migration of NSCLC cells. Our data demonstrate that MCs improve IL-8-Wnt/β-Catenin signaling pathway that induces EMT and migration in NSCLC cells. Consistent with these results, β-Catenin induced NSCLC proliferation, EMT and invasion in NSCLC which validate our data [14, [32] [33] . Although the NSCLC cells exhibit diverse phenotypes of mast cell density, there is still no significant relationships with estimated clinical outcome. Moreover, in NSCLC samples, we also obtain that MC density is positive correlation with the prognosis. High density of MC in NSCLC is worse overall survival (OS). In fact, NSCLC prognosis is usually complicated, most of patients are cured upon surgery and chemotherapy. In future, the immunotherapy, MC inhibitor chromoglycate (Cromolyn) maybe serves as a novel target to impede migration of NSCLC.
MCs are a main source of IL-8 in NSCLC, as described in the present research. However, we still cannot eliminate other kinds of cell types which play a vital role to construct the tumor microenvironment. It may stand for that there is an alternative source of IL-8 instead of NSCLC. And this research is needed for further investigation. Original data suggest that among all kinds of immune cells which can infiltrate NSCLC, macrophages produces high expressions of IL-8 production. There is a report indicates that tumor-associated macrophages (TAMs) induce high level of IL-8 in NSCLC, and IL-8 in turn promotes NSCLC angiogenesis and the survival of patients [34] . Moreover, TAMs are also rich in human NSCLC, where their density is associated with cancer metastasis [35] . It means that different immune cells can induce NSCLC growth. In our preliminary data indicate that TAMs can produce high level of IL-8 in NSCLC. It is imperative for us to further investigation.
Taken together, our data identify NSCLC release CCL5, which receptor located at the MCs surface, combined its receptor and activated MCs secret IL-8. MC-dependent IL-8-Wnt/β-Catenin pathway that induces EMT and migration of NSCLC cells ( Figure  9 ). The obstruction of this circuit can be used for the precise therapy of advanced NSCLC. However, our study also came up with several questions. First and foremost, are MCs an absolute demand for NSCLC formation? Second, the underlying mechanism of NSCLC releases CCL5 to recruit mast cell to tumor micro-environment is still unknown. We are going to perform experiments of impeding MC development in animal models or cells to further solve this issue both in vivo and in vitro in future.
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